Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up Following Analyst Upgrade

Key Points

• JPMorgan upgraded Bayer from neutral to overweight, sending the stock to a pre-market gap up (closed $10.10, opened $10.40) and it last traded around $10.48 on volume ~130,543 shares.
• Analyst sentiment is mixed but positive overall — MarketBeat shows a consensus Buy (2 Strong Buy, 3 Buy, 1 Hold), with recent moves including Morgan Stanley also upgrading to overweight and Zacks cutting to hold.
• Fundamentals show a $41.32 billion market cap and a negative P/E (-116.82), while the stock is trading above its 50‑day ($8.25) and 200‑day ($8.01) moving averages.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report)'s share price gapped up prior to trading on Tuesday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. The stock had previously closed at $10.10, but opened at $10.40. Bayer Aktiengesellschaft shares last traded at $10.4810, with a volume of 130,543 shares trading hands.

Several other research firms have also recently weighed in on BAYRY. Zacks Research cut shares of Bayer Aktiengesellschaft from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 3rd. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an "equal weight" rating to an "overweight" rating in a report on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

The company's 50 day moving average price is $8.25 and its 200-day moving average price is $8.01. The stock has a market cap of $41.32 billion, a P/E ratio of -116.82, a price-to-earnings-growth ratio of 4.90 and a beta of 0.69. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.